Criteria | Response | N* | HR | 95% CI | P | C-index |
---|---|---|---|---|---|---|
PSA50 | PD vs. no-PD | 42 vs. 61 | 4.8 | 2.5–9.3 | <0.001 | 0.695 (0.629–0.761) |
aPERCIST | PD vs. no-PD | 33 vs. 70 | 8.1 | 4.1–16.2 | <0.001 | 0.746 (0.690–0.802) |
PD vs. SD | 33 vs. 18 | 4.1 | 1.7–10.1 | <0.001 | ||
PD vs. PR/CR | 33 vs. 52 | 11.4 | 4.7–27.1 | <0.001 | ||
aPCWG3 | PD vs. no-PD | 34 vs. 69 | 7.1 | 3.5–14.2 | <0.001 | 0.729 (0.670–0.788) |
PPP | PD vs. no-PD | 41 vs. 62 | 8.1 | 4.0–16.7 | <0.001 | 0.765 (0.721–0.808) |
n/m = unmeasurable disease; PSA50 = dichotomous, biochemical response with PSA reduction ≥ 50%; *Number of patients.